Weight loss injections for people without diabetes: what you need to know

You've been told these are 'diabetes jabs', here's the fuller picture

It's a reasonable thing to wonder. Tirzepatide (Mounjaro) was first developed in diabetes research, and semaglutide appears in both Ozempic, which treats type 2 diabetes, and Wegovy, which is licensed for weight management. That overlap creates genuine confusion. The short answer is that the weight-management licences are entirely separate and were granted on the strength of dedicated obesity trials in people who did not have diabetes.

In the SURMOUNT-1 trial (which enrolled over 2,500 adults with obesity and without diabetes) participants taking the highest dose of tirzepatide lost an average of around 20–21% of their body weight over 72 weeks, as published in the New England Journal of Medicine. The STEP 1 trial for semaglutide 2.4mg similarly recruited non-diabetic participants, with average weight reductions of around 15% over 68 weeks. These are the trial populations the licences were built on. If you want to understand the overlap between the two medicines before your consultation, the relationship between these injections and diabetes treatment is worth reading through.

Ozempic and Rybelsus, by contrast, are licensed for type 2 diabetes management only. Presenting for weight loss and being given Ozempic would be off-label; it is not what reputable UK prescribers do for this purpose, and it is not what nume prescribes. If you're researching how a diabetes weight loss injection works and how it differs from the weight-management-licensed versions, that page sets out the distinction clearly. Worth being clear on that distinction from the start.

Who qualifies for a weight loss injection without a diabetes diagnosis

The licensed criteria for both medicines follow the same broad framework. Adults with a BMI of 30 or above qualify on that basis alone. Adults with a BMI between 27 and 29.9 can also be eligible if they have at least one weight-related condition, examples include high blood pressure, high cholesterol, obstructive sleep apnoea, or prediabetes. A diabetes diagnosis is not required and, for most people seeking treatment through a private route, it won't be present.

Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, in line with NICE's appraisal of tirzepatide (TA1026). BMI is the starting point, not the whole story. A prescriber weighs your medical history, current medications, contraindications, and what you're trying to achieve. Conditions such as a personal or family history of medullary thyroid carcinoma, active pancreatitis, or certain gastrointestinal problems would require careful discussion or might preclude treatment, this is precisely what the clinical assessment is for.

If you're not sure where you sit, the NHS BMI calculator gives you a starting reference point before you book. A prescriber's review is still the step that counts.

Safety considerations that matter most for non-diabetic patients

For people without diabetes, there is no added concern about blood sugar becoming dangerously low, that's a risk profile more relevant to people on insulin or certain diabetes drugs. The side-effect pattern is largely the same regardless of diabetic status: nausea, loose stools, constipation, reflux, and fatigue are the most commonly reported effects, typically peaking in the first few weeks after starting or after a dose increase, then settling for most people. The NHS patient information for tirzepatide covers the full list clearly.

One safety point deserves particular attention. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk across GLP-1 medicines. Severe stomach pain that reaches through to the back (especially with vomiting) warrants urgent medical attention, not a wait-and-see approach. Report any suspected side effect through the MHRA's Yellow Card scheme, which also accepts reports about suspect sellers. For non-diabetic patients who have no existing clinical team monitoring them for the condition, building a clear sense of these warning signs before you start is sensible.

Pregnancy, breastfeeding, and trying to conceive are firm exclusions. These medicines are not licensed for use in pregnancy and are not recommended for anyone actively trying to conceive. Women of childbearing age using oral contraceptive pills and starting tirzepatide should use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be affected. If that changes your situation, discuss it with your prescriber before your first pen. An overview of available weight management treatments can help you compare options if injection therapy isn't the right fit right now.

Getting started through a private clinic if you don't have diabetes

The NHS route to these medicines involves strict eligibility criteria and, in most areas, meaningful waits. For Mounjaro, NHS access is currently phased, early cohorts require a BMI of 40 or above plus multiple weight-related conditions. Most non-diabetic adults seeking treatment today don't meet those criteria yet, which is why private prescribing exists as a regulated alternative. Our page covering the new injection for weight loss and diabetes explains how the latest approvals have changed what's available and to whom.

At nume, the process runs the same way for everyone. You complete a consultation, upload photo ID, and verify your weight on a short video call. A named prescriber on our clinical team (you can read about our clinical lead if you'd like to know who's behind the process) reviews your answers the same day. If the treatment is appropriate, your prescription is issued and the medicine is dispatched from our GPhC-registered pharmacy (registration 9012878, verifiable at the GPhC register). It arrives the next working day via DPD, in plain, unbranded packaging, a discreet box with your name on it, nothing else visible from the outside.

If injection therapy isn't right for you, or if you'd prefer to explore oral options, our guide to non-injection weight loss treatment covers what else is licensed and available in the UK. If you're based in Nevada and want clinic-specific guidance, our weight loss injections Reno page has the local detail you need. Suitability is always a clinical decision, and our prescribers are here to help you work it through. Start your free consultation when you're ready.